Stay updated with breaking news from Select Scope. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year’s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity.
Successfully Met Goals Outlined in MassBio's Diversity, Equity, and Inclusion (DE&I) Industry Pledge -New Disclosures of Company's Impact on Planet-Including Multiyear Data on Scope 1, Scope 2, and Select
Alnylam Issues 2022 Corporate Responsibility Report